September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Lipoxin A4 Regulates T cell Responses in Experimental Autoimmune Uveitis
Author Affiliations & Notes
  • Jessica Wei
    Vision Science, University of California, Berkeley, Berkeley, California, United States
  • Victoria Ly
    Vision Science, University of California, Berkeley, Berkeley, California, United States
  • Karsten Gronert
    Vision Science, University of California, Berkeley, Berkeley, California, United States
  • Footnotes
    Commercial Relationships   Jessica Wei, None; Victoria Ly, None; Karsten Gronert, None
  • Footnotes
    Support  EY022208
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 491. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jessica Wei, Victoria Ly, Karsten Gronert; Lipoxin A4 Regulates T cell Responses in Experimental Autoimmune Uveitis. Invest. Ophthalmol. Vis. Sci. 2016;57(12):491.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : CD4 T cells differentiate into T helper subsets and T regulatory cells to initiate or control adaptive immune responses. Aberrant T cell response during ocular inflammation can result in irreversible tissue damage that leads to blindness. We recently published that T effector functions is controlled by lipoxin A4 (LXA4) in an autoimmune dry eye model, demonstrated by LXA4 formation in the cervical draining lymph nodes. LXA4 is generated in tissues and lymph nodes and mediates its effects by signaling through the GPCR ALX, which is expressed in T cells. We sought to understand whether LXA4 regulates T cell response in experimental autoimmune uveitis (EAU) and AIRE knockout mouse models, which recapitulate key features of spontaneous and chronic uveitis that is driven by autoreactive T cells.

Methods : LXA4 regulation of T effector and T regulatory cells was assessed in vitro and in vivo using flow cytometry and cytokine/chemokine arrays. Lipidomic analyses and QPCR were used to compare levels of lipid mediator (LM) formation and expression of biosynthetic enzymes and LM receptors in EAU and AIRE knockout mouse models. LXA4’s ability to inhibit uveitis pathogenesis was assessed by OCT and immunohistology.

Results : LXA4 levels in the healthy choroid and retina and during uveitis pathogenesis ranged from from 47-85 pg/eye. In vitro, LXA4 inhibits T effector cells and amplifies TGF-β and IL-2 induced Treg polarization by 90% (p=0.0038, n=5). In vivo, treatment with LXA4 was protective and limited inflammation and disease progression of EAU.

Conclusions : The findings demonstrate for the first time that the immune regulatory LXA4 is formed in the retina and choroid and is a significant LM mediating the pathogenesis of posterior autoimmune uveitis. In vitro and in vivo data demonstrate that the LXA4 circuit is protective and a key regulator of T cell driven uveitis. Emerging evidence demonstrates LXA4 regulation of adaptive immune responses and delineating the mechanism of action warrants further investigation.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×